Other Research Opportunities
Several other funding sources also offer support for students and researchers in the field of inflammatory bowel diseases (IBD).
AGA Pfizer JAK-IBD Research Grant
The AGA Research Foundation and Pfizer, Inc. are pleased to announce the new AGA-Pfizer JAK-IBD Research Grant. This award provides up to $100,000 per year for two years (total $200,000) to an investigator interested in studying the role of Janus kinase (JAK) pathways in the pathophysiology and immunology of inflammatory bowel disease (IBD).
Unlike other awards from the AGA Research Foundation, there are no geographic or applicant age restrictions to apply. Candidates must hold an MD, PhD or equivalent degree (e.g., MB, ChB, MBBS, DO) and a full-time faculty position at a nonprofit institution. The application deadline is June 6, 2014. Funding will commence in October 2014.
Applications must be submitted to both Pfizer, Inc. and the AGA Research Foundation; detailed submission instructions are available on the AGA website.
A subcommittee of the AGA Research Foundation Awards Panel will review all applications and select the recipient based on significance and implications of the research to the treatment of IBD, innovation, approach, the applicant’s research environment, and evidence of institutional commitment.
The University of Miami Miller School of Medicine
The University of Miami Miller School of Medicine, Division of Gastroenterology and Crohn’s and Colitis Center, is announcing a one-year Advanced IBD Fellowship for qualified, board certified or board eligible individuals who will have completed an adult or pediatric gastroenterology fellowship within the last five years. The year will combine clinical IBD training, advanced IBD-related procedures, and research. Procedural skills include chromoendoscopy, deep small bowel enteroscopy and perianal endoscopic ultrasonography. Approximately 50% of the time will be devoted to clinical and/or translational research in inflammatory bowel diseases, which includes genotype-phenotype studies using our IBD registry and investigator-initiated and pharmaceutical-sponsored clinical trials. Educational exposure to the role of mucosal immunology, genetics, and intestinal biology in caring for IBD patients will be stressed. If you are interested in this opportunity, please e-mail Amar R. Deshpande, M.D.
The Kenneth Rainin Foundation
The Kenneth Rainin Foundation believes that finding causes and cures for IBD will require bold and creative ideas that expand our ability to further explore and conquer these challenges. To accelerate the pace of discovery in IBD research, the Foundation is launching a new award—the Kenneth Rainin Foundation Innovator Awards Program for IBD Research.
National Institutes of Health
The National Institutes of Health (NIH) conducts and supports biomedical research as well as disseminating research findings and health information to the public. NIH is part of the U.S. Government, under the Department of Health and Human Services (HHS). Two main institutes at NIH, the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute for Allergies and Infectious Diseases (NIAID), provide funding for IBD-related research.
The Crohn’s and Colitis Foundation of Canada
Grants in Aid of Research
The Crohn’s and Colitis Foundation of Canada (CCFC) Grants in Aid (GIA) of Research program is intended to support research on IBD. Grants are awarded to investigators working alone or in collaboration with others. Grants will be awarded for a maximum of three years, not to exceed $125,000 per annum.
The CCFC Visiting Scientist Program
The CCFC Visiting Scientist Program is designed to allow Canadian institutions to bring in productive scientists having expertise not available within the institution, and to allow Canadian scientists to visit major international research centers in order to acquire knowledge or new techniques related to IBD research.
Innovations in IBD Research—A Special Competition
The CCFC invites applications for an "Innovations Grant” to fund novel or innovative approaches to IBD research. This grant is intended to stimulate and support research which may not be encompassed within the boundaries of traditional medical research. Research proposals must conform to sound principles of research and may aim to collect pilot data for follow-on application(s). The CCFC seeks mission relevance and excellence as well as innovation.
CCFC Strategic Priority Partnership Initiative
To address priorities outlined in the current strategic plan, the CCFC is inviting proposals which include partnering with financial supporter(s) and focusing on clinical/translational, epidemiological, and/or health service questions relevant to IBD. To augment the historical emphasis on basic science and biomedical research ("Pillar I research" as defined by CIHR), the CCFC strategic plan prioritizes a diversification of research investment. Doing so in partnership with other organizations that share these common scientific interests and that are able to co-fund projects will help make this possible. Two examples of potential partners would include provinces in need of better prevalence estimates for IBD and organizations interested in sponsoring clinical/translational research that requires funding at levels exceeding the capacity of current CCFC programs.
Partnerships may be negotiated and described in a cover letter with other supporting documentation appended to a full proposal using the most current GIA application form available. Applications received through this partnership initiative will be reviewed along with those submitted for the yearly GIA competition in the spring.
Final positive decisions regarding funding any such partnership project(s) will be contingent on scientific merit, relevance to the mission and fitting with the strategic priorities of the CCFC, as well as partner funding at a minimum of 50% of the total project budget. While final decisions regarding co-funding from partners need not be in place when proposals are submitted, funding from the CCFC will not be approved until matching (or better) dollars are committed by the partner(s). The maximum amount of co-funding from the CCFC for this partnership initiative is $125,000 per year for up to three years (same as the GIA program).
Participate in Research Studies
CCFA fosters and supports programs of basic research, clinical trials, observational studies and education projects as they relate to its mission to cure Crohn's disease and ulcerative colitis and to improve the quality of life of children and adults affected by these diseases.
Click on the link(s) below to participate in current research studies for healthcare professionals:
- International Practice Variation of Diagnosis & Treatment of IBD
- Physician opinions and preferences for withdrawal of combination therapy for patients with Crohn’s disease who are in remission
- Premedication usage for IBD patients on infliximab
- Use of Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease Patients with Heart Failure